Immunotherapy plus chemo: a new hope for head and neck cancer?
NCT ID NCT02997332
First seen Mar 26, 2026 · Last updated Jun 22, 2026 · Updated 14 times
Summary
This early-phase trial tested whether adding the immunotherapy drug durvalumab to standard chemotherapy (docetaxel, cisplatin, and 5-FU) is safe for people with advanced head and neck cancer. The study enrolled 14 adults with untreated, non-spread cancer. The goal was to find the right dose and check for side effects. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gustave Roussy
Villejuif, Val de Marne, 94805, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (an immunotherapy drug) combined with docetaxel, cisplatin, and 5-fluorouracil (chemotherapy drugs)
What this could lead to
If successful, this combination could improve the effectiveness of induction chemotherapy for advanced head and neck cancer, potentially improving survival.
What could go wrong
This was a very early (Phase 1) safety study that was terminated early with only 14 participants. The combination may cause severe side effects or not work better than standard treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.